NCT04164212

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 33 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 18 Years – 49 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to develop a nasal model for influenza infection using the live attenuated influenza vaccine (LAIV). The investigators will administer LAIV to healthy adult volunteers in order to simulate influenza infection, and obtain nasal specimens to measure influenza virus and inflammatory/immune responses. In a subset of participants, cystic fibrosis transmembrane conductance regulator (CFTR) function will also be evaluated via measurement of nasal potential difference (NPD)

Conditions

• Influenza

Interventions

Type	Name	Description
DRUG	Flumist Quadrivalent Nasal Product	FLUMIST QUADRIVALENT 0.2 mL dose supplied in a single-dose pre-filled intranasal sprayer

Timeline

• Start date: 2020-09-01
• Primary completion: 2026-01-22
• Completion: 2026-01-22
• First posted: 2019-11-15
• Last updated: 2026-02-20

Locations

1 site across 1 country: United States